Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies

References

• Gray-SchopferVWellbrockCMaraisRMelanoma biology and new targeted therapyNature2007445713085185717314971
   PubMed Web of Science ®Google Scholar
• SullivanRJFisherDEUnderstanding the biology of melanoma and therapeutic implicationsHematol Oncol Clin North Am201428343745324880940
   PubMed Web of Science ®Google Scholar
• ThompsonJFScolyerRAKeffordRFCutaneous melanoma in the era of molecular profilingLancet2009374968736236519647595
   PubMed Web of Science ®Google Scholar
• ArozarenaISanchez-LaordenBPackerLOncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5ACancer Cell2011191455721215707
   PubMed Web of Science ®Google Scholar
• FlahertyKTMcArthurGBRAF, a target in melanoma: implications for solid tumor drug developmentCancer2010116214902491320629085
   PubMed Web of Science ®Google Scholar
• PackerLMEastPReis-FilhoJSMaraisRIdentification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanomaPigment Cell Melanoma Res200922678579819682280
   PubMed Web of Science ®Google Scholar
• HauschildAGrobJJDemidovLVDabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialLancet2012380983935836522735384
   PubMed Web of Science ®Google Scholar
• WellbrockCHurlstoneABRAF as therapeutic target in melanomaBiochem Pharmacol201080556156720350535
   PubMed Web of Science ®Google Scholar
• PalitVEardleyIAn update on new oral PDE5 inhibitors for the treatment of erectile dysfunctionNat Rev Urol201071160360921068761
   PubMed Web of Science ®Google Scholar
• ScaglioneFDondeSHassanTAJanniniEAPhosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction: pharmacology and clinical impact of the sildenafil citrate orodispersible tablet formulationClin Ther201739237037728139291
   PubMed Web of Science ®Google Scholar
• VentimigliaECapogrossoPMontorsiFSaloniaAThe safety of phosphodiesterase type 5 inhibitors for erectile dysfunctionExpert Opin Drug Saf201615214115226752541
   PubMed Web of Science ®Google Scholar
• KasumiSIn vitro effects of a phosphodiesterase inhibitor sildenafil on cellular motility of the oral malignant melanoma cellsJ Oral Maxillofac Surg2014729e96e97
   Google Scholar
• DhayadeSCNP-derived cGMP and Sildenafil promote melanoma growth in vitro and in vivo in miceNaunyn-Schmiedeberg’s Archives of Pharmacology20153881S13
   Google Scholar
• DhayadeSKaeslerSSinnbergTSildenafil potentiates a cGMP-dependent pathway to promote melanoma growthCell Rep201614112599261026971999
   PubMed Web of Science ®Google Scholar
• LiWQQureshiAARobinsonKCHanJSildenafil use and increased risk of incident melanoma in US men: a prospective cohort studyJAMA Intern Med2014174696497024710960
   PubMed Web of Science ®Google Scholar
• LoebSFolkvaljonYLambeMUse of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant MelanomaJAMA2015313242449245526103029
   PubMed Web of Science ®Google Scholar
• BoorPMelanoma in men treated with PDE5A inhibitors: A report from the RADAR (research on adverse drug events and reports) projectJ Am Acad Dermatol2016745 Suppl 1AB190
   Web of Science ®Google Scholar
• LianYYinHPollakMNPhosphodiesterase type 5 inhibitors and the risk of melanoma skin cancerEur Urol201670580881527178449
   PubMed Web of Science ®Google Scholar
• MatthewsALanganSMDouglasIJSmeethLBhaskaranKPhosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalinkPLoS Med2016136e100203727299522
   PubMed Web of Science ®Google Scholar
• PottegardASchmidtSAOlesenABUse of sildenafil or other phosphodiesterase inhibitors and risk of melanomaBr J Cancer2016115789590027529513
   PubMed Web of Science ®Google Scholar
• KearnsJTLapinBWangEAssociations between iCOGS single nucleotide polymorphisms and upgrading in both surgical and active surveillance cohorts of men with prostate cancerEur Urol201669222322826411806
   PubMed Web of Science ®Google Scholar
• StroupDFBerlinJAMortonSCMeta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) groupJAMA2000283152008201210789670
   PubMed Web of Science ®Google Scholar
• HigginsJGreenSCochrane Handbook for Systematic Reviews of Interventions Version 5.1.0The Cochrane Collaboration2011 Available from: www.cochranehandbook.orgAccessed April 14, 2017
   Google Scholar
• WellsGASheaBO’ConnellDThe Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses2010 Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.aspAccessed April 14, 2017
   Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• PatsopoulosNAEvangelouEIoannidisJPSensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluationInt J Epidemiol20083751148115718424475
   PubMed Web of Science ®Google Scholar
• EggerMDavey SmithGSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ199731571096296349310563
   PubMed Web of Science ®Google Scholar
• SicaAMassarottiMMyeloid suppressor cells in cancer and autoimmunityJ Autoimmun Epub2017717
   Web of Science ®Google Scholar
• SerafiniPMeckelKKelsoMPhosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell functionJ Exp Med2006203122691270217101732
   PubMed Web of Science ®Google Scholar
• MeyerCSevkoARamacherMChronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma modelProc Natl Acad Sci U S A201110841171111711621969559
   PubMed Web of Science ®Google Scholar
• NoonanKAGhoshNRudrarajuLBuiMBorrelloITargeting immune suppression with PDE5 inhibition in end-stage multiple myelomaCancer Immunol Res20142872573124878583
   PubMed Web of Science ®Google Scholar
• UmanskyVSildenafil prolongs survival and reduces immunosuppression in ret transgenic mouse melanoma modelEur J Immunol200939S324
   Google Scholar
• WeedDTVellaJLReisIMTadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinomaClin Cancer Res2015211394825320361
   PubMed Web of Science ®Google Scholar
• CalifanoJAKhanZNoonanKATadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinomaClin Cancer Res2015211303825564570
   PubMed Web of Science ®Google Scholar
• HasselJCJiangHBenderCTadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe)Oncoimmunology201769e132644028932631
   PubMed Web of Science ®Google Scholar
• BarbourAPTangYHArmourNBRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapyEur J Cancer201450152668267625070294
   PubMed Web of Science ®Google Scholar
• Santiago-WalkerAGagnonRMazumdarJCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsClin Cancer Res201622356757426446943
   PubMed Web of Science ®Google Scholar
• SiroyAEAungPPTorres-CabalaCAClinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanomaHum Pathol201759485427666765
   PubMed Web of Science ®Google Scholar
• KimSYKimSNHahnHJLeeYWChoeYBAhnKJMetaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanomaJ Am Acad Dermatol201572610361046.e225819940
   PubMed Web of Science ®Google Scholar